CA2914261C - Anti-fibrogenic compounds, methods and uses thereof - Google Patents
Anti-fibrogenic compounds, methods and uses thereof Download PDFInfo
- Publication number
- CA2914261C CA2914261C CA2914261A CA2914261A CA2914261C CA 2914261 C CA2914261 C CA 2914261C CA 2914261 A CA2914261 A CA 2914261A CA 2914261 A CA2914261 A CA 2914261A CA 2914261 C CA2914261 C CA 2914261C
- Authority
- CA
- Canada
- Prior art keywords
- img
- och3
- compound
- fibrosis
- following
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831404P | 2013-06-05 | 2013-06-05 | |
| US61/831,404 | 2013-06-05 | ||
| PCT/CA2014/000484 WO2014194407A1 (en) | 2013-06-05 | 2014-06-04 | Anti-fibrogenic compounds, methods and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2914261A1 CA2914261A1 (en) | 2014-12-11 |
| CA2914261C true CA2914261C (en) | 2020-02-11 |
Family
ID=52007349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2914261A Active CA2914261C (en) | 2013-06-05 | 2014-06-04 | Anti-fibrogenic compounds, methods and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9737523B2 (enExample) |
| EP (1) | EP3003298B1 (enExample) |
| JP (1) | JP6473938B2 (enExample) |
| KR (1) | KR102294405B1 (enExample) |
| AU (1) | AU2014277568B2 (enExample) |
| CA (1) | CA2914261C (enExample) |
| DK (1) | DK3003298T3 (enExample) |
| ES (1) | ES2978920T3 (enExample) |
| PH (1) | PH12015502717B1 (enExample) |
| PL (1) | PL3003298T3 (enExample) |
| RU (1) | RU2726416C2 (enExample) |
| SG (1) | SG11201510003VA (enExample) |
| WO (1) | WO2014194407A1 (enExample) |
| ZA (1) | ZA201600015B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018144461A1 (en) | 2017-01-31 | 2018-08-09 | The Board Of Regents Of The University Of Oklahoma | Animal wound model and methods of use |
| CN112168822B (zh) * | 2020-09-27 | 2022-11-08 | 集美大学 | 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途 |
| JP2024517463A (ja) * | 2021-05-04 | 2024-04-22 | ソヴィダ ソリューションズ リミテッド | ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法 |
| KR20240004954A (ko) * | 2021-05-07 | 2024-01-11 | 바치바이오메드 인크. | 소분자 화합물을 사용하여 여드름-후 위축성 흉터의 외관을 개선하는 방법 (methods of using a small molecule chemical compound to reduce the appearance of post-acne atrophic scarring) |
| EP4572737A1 (en) * | 2022-09-14 | 2025-06-25 | Birchbiomed Inc. | Methods of using a small molecule chemical compound to reduce the appearance of rhytids and wrinkles |
| US20240189279A1 (en) * | 2022-12-11 | 2024-06-13 | The Texas A&M University System | Immunomodulatory compositions and methods of use thereof |
| CN119055650A (zh) * | 2024-09-06 | 2024-12-03 | 上海市东方医院（同济大学附属东方医院） | 犬尿喹啉酸在治疗慢性肝硬化中的应用 |
| PL450606A1 (pl) | 2024-12-16 | 2026-06-22 | Uniwersytet Łódzki | Zastosowanie tryptofanu lub jego metabolitów ze szlaku kynureninowego w profilaktyce i leczeniu dermatofitoz oraz kompozycja farmaceutyczna do stosowania zewnętrznego |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| EP1369114A1 (en) | 2002-06-07 | 2003-12-10 | Peter Priv. Doz. Dr. Terness | Use of tryptophan metabolites as pharmaceutical agents |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| WO2006053390A1 (en) * | 2004-11-17 | 2006-05-26 | Angiogen Pharmaceuticals Pty. Ltd. | A method of modulating b cell functioning |
| HUP0700051A2 (en) * | 2007-01-17 | 2008-09-29 | Univ Szegedi | Use of kynurenic acid and derivatives there of for treating of gastrointestinal disorders associated with enhanced motility and inflammation |
| KR20150021071A (ko) * | 2012-06-15 | 2015-02-27 | 코나리스 리써치 인스티튜트 아게 | 니코틴산 및/또는 니코틴아미드 및/또는 트립토판을 포함하는 장내 세균총에 유익한 효능을 가진 약학 조성물 |
-
2014
- 2014-06-04 SG SG11201510003VA patent/SG11201510003VA/en unknown
- 2014-06-04 ES ES14806967T patent/ES2978920T3/es active Active
- 2014-06-04 US US14/896,269 patent/US9737523B2/en active Active
- 2014-06-04 KR KR1020167000203A patent/KR102294405B1/ko active Active
- 2014-06-04 DK DK14806967.7T patent/DK3003298T3/da active
- 2014-06-04 AU AU2014277568A patent/AU2014277568B2/en active Active
- 2014-06-04 JP JP2016517101A patent/JP6473938B2/ja active Active
- 2014-06-04 WO PCT/CA2014/000484 patent/WO2014194407A1/en not_active Ceased
- 2014-06-04 CA CA2914261A patent/CA2914261C/en active Active
- 2014-06-04 RU RU2015156196A patent/RU2726416C2/ru active
- 2014-06-04 EP EP14806967.7A patent/EP3003298B1/en active Active
- 2014-06-04 PH PH1/2015/502717A patent/PH12015502717B1/en unknown
- 2014-06-04 PL PL14806967.7T patent/PL3003298T3/pl unknown
-
2016
- 2016-01-04 ZA ZA2016/00015A patent/ZA201600015B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3003298T3 (pl) | 2024-07-15 |
| US20160120857A1 (en) | 2016-05-05 |
| AU2014277568B2 (en) | 2019-09-19 |
| CA2914261A1 (en) | 2014-12-11 |
| JP6473938B2 (ja) | 2019-02-27 |
| WO2014194407A1 (en) | 2014-12-11 |
| JP2016521695A (ja) | 2016-07-25 |
| PH12015502717A1 (en) | 2016-03-14 |
| RU2726416C2 (ru) | 2020-07-14 |
| SG11201510003VA (en) | 2016-01-28 |
| RU2015156196A3 (enExample) | 2018-05-24 |
| RU2015156196A (ru) | 2017-07-14 |
| KR102294405B1 (ko) | 2021-08-25 |
| EP3003298A1 (en) | 2016-04-13 |
| NZ715579A (en) | 2021-05-28 |
| AU2014277568A1 (en) | 2016-01-28 |
| KR20160018676A (ko) | 2016-02-17 |
| ZA201600015B (en) | 2019-07-31 |
| EP3003298A4 (en) | 2017-03-22 |
| PH12015502717B1 (en) | 2023-09-13 |
| US9737523B2 (en) | 2017-08-22 |
| DK3003298T3 (da) | 2024-06-17 |
| EP3003298B1 (en) | 2024-03-20 |
| BR112015030569A2 (pt) | 2017-07-25 |
| BR112015030569A8 (pt) | 2020-01-07 |
| ES2978920T3 (es) | 2024-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014277568B2 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| Lu et al. | Nesfatin-1 functions as a switch for phenotype transformation and proliferation of VSMCs in hypertensive vascular remodeling | |
| Luo et al. | Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-β1/SMADs pathway | |
| EP3229831B1 (en) | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors | |
| Wang et al. | Apelin attenuates TGF-β1-induced epithelial to mesenchymal transition via activation of PKC-ε in human renal tubular epithelial cells | |
| Zanotti et al. | Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-β1 treatment | |
| JP2022512516A (ja) | ケロイドまたは肥厚性瘢痕の予防または治療用組成物 | |
| He et al. | Pharmacological regulation of tissue fibrosis by targeting the mechanical contraction of myofibroblasts | |
| US12006501B2 (en) | Composition of drug targets and method of using thereof | |
| Huang et al. | A novel caffeic acid derivative prevents renal remodeling after ischemia/reperfusion injury | |
| Riaz et al. | Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B | |
| JP7297104B2 (ja) | 特発性肺線維症の動物モデル、その構築方法及び使用 | |
| KR20180010245A (ko) | 저산소증 신호전달 유전자를 저해하기 위한 ape1/ref-1을 표적화하는 방법 | |
| WO2015093901A1 (ko) | Taz 단백질 활성화 유도 성분을 포함하는 근육 분화 및 근육재생용약학적조성물 | |
| JP2009521928A (ja) | 神経細胞変性疾患の治療に有用な化合物を特定する方法 | |
| CN115475167B (zh) | Cdc20抑制剂在制备用于减轻肾脏纤维化的药物中的用途 | |
| Zhan et al. | Leucine-rich repeats and immunoglobulin 1 (LRIG1) ameliorates liver fibrosis and hepatic stellate cell activation via inhibiting sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P) pathway | |
| NZ715579B2 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| Wang et al. | A CD36 synthetic peptide inhibits silica-induced lung fibrosis in the mice | |
| Ding et al. | Transferrin receptor (Tfr1) ablation in satellite cells impacts skeletal muscle regeneration through the activation of ferroptosis | |
| Cheng et al. | Role of TRIM59 in regulating PPM1A in the pathogenesis of silicosis and the intervention effect of tanshinone IIA | |
| BR112015030569B1 (pt) | Uso de compostos anti-fibrogênicos | |
| Liu et al. | Erythropoietin alleviate obstructive renal fibrosis by regulating immunity and inflammation through miR-21-5p/SPRY1/ERK1/2/NF-κB pathway inhibition | |
| Li et al. | The role of TRPC6-mediated autophagy in myocardial ischaemia/reperfusion injury | |
| Waters | CXCR4 regulates migration of lung alveolar epithelial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190130 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250520 |